BIOGEN IDEC INC (BIIB) 59.20 -$0.16 (-0.27%) 10:55PM (15 mins delay)

Biogen Idec -- BIIB is being added to my Marketocracy S&P 500 model portfolio. IDEC Pharmaceuticals Corporation is a biopharmaceutical company engaged primarily in the research, development and commercialization...

Read complete stock pick on BIIB

Massachusetts-based Biogen Idec (Nasdaq: BIIB, $50.50) specializes in the development of therapies aimed at the fields of oncology, neurology, cardiology and autoimmune disorders. Major products include...

Read complete stock pick on BIIB

Carl Icahn owns 10% of Biogen now and has initiated a proxy battle. He will do what he always does: replace board members until the board agrees that the company must be sold, Then he will find a buyer....

Read complete stock pick on BIIB

We are one month away from earnings. This stock has beat Q4 earnings from a year prior in its last Q4 report and is projected to beat its Q1 earnings from a year prior in this next Q1 report. This is...

Read complete stock pick on BIIB

Biogen is an established pharmaceutical company with ambitious plans for the coming months. Riding the wake of it's successful MS injection Tysbari, Biogen has successfully created a pill version of a...

Read complete stock pick on BIIB